BLOOMBERG | As bacteria become increasingly resistant to antibiotics, the pipeline of drugs to counter so-called superbugs has virtually dried up. Three years after announcing a strategy to boost investment in antibiotics, England is poised to fund a pair of new drugs by offering companies a fixed annual fee regardless of how much—or how little—they’re used.